Oral administration of nimbolide, over 12 weeks shows reduction of prostate tumour size by up to 70 per cent and decrease in tumour metastasis by up to 50 per cent
A team of international researchers led by Associate Professor Gautam Sethi from the Department of Pharmacology at the Yong Loo Lin School of Medicine at the National University of Singapore (NUS) has found that nimbolide, a bioactive terpenoid compound derived from Azadirachta indica or more commonly known as the neem plant, could reduce the size of prostate tumour by up to 70 per cent and suppress its spread or metastasis by half.
Prostate cancer is one of the most commonly diagnosed cancers worldwide. However, currently available therapies for metastatic prostate cancer are only marginally effective. Hence, there is a need for more novel treatment alternatives and options.
“Although the diverse anti-cancer effects of nimbolide have been reported in different cancer types, its potential effects on prostate cancer initiation and progression have not been demonstrated in scientific studies. In this research, we have demonstrated that nimbolide can inhibit tumour cell viability – a cellular process that directly affects the ability of a cell to proliferate, grow, divide, or repair damaged cell components – and induce programmed cell death in prostate cancer cells,” said Assoc Prof Sethi.
Nimbolide: promising effects on prostate cancer
Cell invasion and migration are key steps during tumour metastasis. The NUS-led study revealed that nimbolide can significantly suppress cell invasion and migration of prostate cancer cells, suggesting its ability to reduce tumour metastasis.
The researchers observed that upon the 12 weeks of administering nimbolide, the size of prostate cancer tumour was reduced by as much as 70 per cent and its metastasis decreased by about 50 per cent, without exhibiting any significant adverse effects.
“This is possible because a direct target of nimbolide in prostate cancer is glutathione reductase, an enzyme which is responsible for maintaining the antioxidant system that regulates the STAT3 gene in the body. The activation of the STAT3 gene has been reported to contribute to prostate tumour growth and metastasis,” explained Assoc Prof Sethi. “We have found that nimbolide can substantially inhibit STAT3 activation and thereby abrogating the growth and metastasis of prostate tumour,” he added.
The findings of the study were published in the April 2016 issue of the scientific journal Antioxidants & Redox Signaling. This work was carried out in collaboration with Professor Goh Boon Cher of Cancer Science Institute of Singapore at NUS, Professor Hui Kam Man of National Cancer Centre Singapore and Professor Ahn Kwang Seok of Kyung Hee University.
Neem – The medicinal plant
The neem plant belongs to the mahogany tree family that is originally native to India and the Indian sub-continent, but is now also commonly found in Singapore. It has been part of traditional Asian medicine for centuries and is typically used in Indian Ayurvedic medicine. Today, neem leaves and bark have been incorporated into many personal care products such as soaps, toothpaste, skincare and even dietary supplements. Neem seedlings can also be obtained from the Indian flower shops at Campbell Lane and Buffalo Road areas within Serangoon Road in Singapore.
The team is looking to embark on a genome-wide screening or to perform a large-scale study of proteins to analyse the side-effects and determine other potential molecular targets of nimbolide. They are also keen to investigate the efficacy of combinatory regimen of nimbolide and approved drugs such as docetaxel and enzalutamide for future prostate cancer therapy.
The Latest on: Prostate cancer
via Google News
The Latest on: Prostate cancer
- VIDEO: TALAPRO-2 trial assesses talazoparib plus enzalutamide for metastatic prostate cancer on June 19, 2019 at 8:07 am
CHICAGO — Neeraj Agarwal, MD, professor of medicine and director of the genitourinary oncology program at The University of Utah’s Huntsman Cancer Institute, presented early safety results of the ... […]
- Local firefighter opens up about challenges after surviving cancer on June 19, 2019 at 7:35 am
Todd Righter was diagnosed with prostate cancer in 2018 and was able to have it surgically removed without chemo. While he says he is blessed to continue his life with his family, he has been ... […]
- Research demonstrating the importance of exercise in cancer care on June 19, 2019 at 5:24 am
Research at Northumbria University, Newcastle is investigating the important role that structured exercise programmes can play in living with and beyond cancer. Cancers of the breast, prostate and ... […]
- Exploring subcellular responses of prostate cancer cells to X-ray exposure by Raman mapping on June 18, 2019 at 2:21 am
Understanding the response of cancer cells to ionising radiation is a crucial step in modern radiotherapy. Raman microspectroscopy, together with Partial Least Squares Regression (PLSR) analysis has ... […]
- With equal access to care, prostate cancer outcomes similar among black, white men on June 17, 2019 at 11:24 am
JAMA Oncol. 2019;doi:10.1001/jamaoncol.2019.0826. After controlling for nonbiological variations such as access to care and standardized treatment, black men with nonmetastatic prostate cancer had ... […]
- LncRNA FOXP4-AS1 is activated by PAX5 and promotes the growth of prostate cancer by sequestering miR-3184-5p to upregulate FOXP4 on June 17, 2019 at 4:40 am
Prostate cancer (PCa) is one of the major men malignancies worldwide. Long noncoding RNAs (lncRNAs) have been reported as essential regulators in human cancers, including PCa. In the present study, ... […]
- Global Prostate Cancer Therapeutics Market Outlook 2015-2022 - Developing Countries Turbo Charge Future Market Growth on June 17, 2019 at 3:45 am
Dublin, June 17, 2019 (GLOBE NEWSWIRE) -- The "Prostate Cancer Therapeutics: Global Market Analysis, Trends, and Forecasts" report has been added to ResearchAndMarkets.com's offering. This report ... […]
- Prostate Cancer and Race on June 16, 2019 at 8:02 am
Over the years, as a staff medical reporter for a large metro daily in Chicago and a freelancer, I have written many stories about health issues affecting African Americans, including access to care, ... […]
- New drug helps men with advanced prostate cancer live longer on June 15, 2019 at 11:21 am
SALT LAKE CITY — A new medication helps men suffering from one of the deadliest forms of cancer live longer, a Huntsman Cancer Institute doctor said. Advanced prostate cancer is the second highest ... […]
via Bing News